http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
CytomX (CTMX) Presents Prelim. Clinical Proof-of-Concept Data from Probody Platform and CX-072 at ASCO
-
CytomX Therapeutics Presents Preliminary Clinical Proof-of-Concept Data from Probody™ Platform and CX-072 at 2018 ASCO Annual Meeting
-
CytomX Announces Conference Call and Webcast to Review PROCLAIM-072 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
-
CytomX to Present at the Jefferies 2018 Healthcare Conference
-
CytomX Therapeutics (CTMX) Announces FDA Clearance of IND Application for CX-2029
-
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-2029, a CD71-Directed Probody Therapeutic
-
CytomX Therapeutics (CTMX) Announces Presentations at ASCO (Yesterday)
-
CytomX Therapeutics Announces Presentations at 2018 ASCO Annual Meeting
-
CytomX Therapeutics Announces First Quarter 2018 Financial Results
-
CytomX to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
-
CytomX Therapeutics to Announce First Quarter 2018 Financial Results
-
CytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational Update
-
CytomX to Present at Upcoming Investor Conferences
-
CytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast Conference Call
-
CytomX Therapeutics Added to NASDAQ Biotechnology Index
-
CytomX Therapeutics (CTMX) Announces FDA Acceptance of IND for CTLA-4 Probody Therapeutic
-
CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic
-
CytomX Announces Third Quarter 2017 Financial Results and Operational Progress
-
CytomX to Present at the Jefferies 2017 London Healthcare Conference
-
CytomX Therapeutics to Announce Third Quarter 2017 Financial Results
-
CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to Board of Directors
-
CytomX Announces Upcoming Poster Presentations at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference
-
Amgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology
-
CytomX to Present at the Cantor Fitzgerald Healthcare Conference
-
CytomX Announces Upcoming Trials in Progress Poster Presentations at European Society for Medical Oncology Annual Meeting
-
CytomX to Present at the 2017 Wedbush PacGrow Healthcare Conference
-
CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call
-
CytomX Therapeutics to Announce Second Quarter 2017 Financial Results and Provide Mid-Year Update
-
CytomX Therapeutics (CTMX) Announces Milestone in Collaboration with AbbVie (ABBV) for CD71-Targeting Probody Drug Conjugate
-
CytomX Achieves Development Milestone in Strategic Oncology Collaboration with AbbVie for CD71-Targeting Probody Drug Conjugate
-
CytomX to Present at the Jefferies 2017 Global Healthcare Conference
-
CytomX Announces Upcoming Poster Presentation at American Society for Clinical Oncology Annual Meeting
-
CytomX Announces Management Team Changes
-
CytomX Announces First Quarter 2017 Financial Results
-
CytomX Therapeutics to Announce First Quarter 2017 Financial Results
-
CytomX Therapeutics (CTMX) Names Marion McCourt to Board of Directors
-
CytomX Therapeutics Appoints Marion McCourt to Board of Directors
-
Bristol-Myers Squibb (BMY), CtomX Therapeutics (CTMX) Extend Strategic Collaboration
-
Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ Therapeutics for the Treatment of Cancer and Other Diseases
-
CytomX Therapeutics Announces Teleconference and Webcast to Provide Corporate Update
-
CytomX Therapeutics to Announce Full-Year 2016 Financial Results
-
Cancer Immunotherapy ETF Celebrates One-Year Anniversary
-
CytomX (CTMX), AbbVie (ABBV) Enter Collaboration to Develop Probody Drug Conjugates Against CD71
-
AbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates
-
CytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates
-
CytomX Therapeutics, Inc. (Nasdaq:CTMX) to Ring The Nasdaq Stock Market Closing Bell
-
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

